• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Olink Holding AB

    2/14/22 4:00:42 PM ET
    $OLK
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OLK alert in real time by email
    SC 13G 1 ea155414-13gsumma_olink.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    OLINK HOLDING AB

     

    (Name of Issuer)

     

    Common Shares, no par value

    American Depositary Shares, each representing one Common Share, no par value**

     

    (Title of Class of Securities)

     

    680710100***

     

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this schedule is filed:

     

    ☐Rule 13d-1(b)
    ☐Rule 13d-1(c)
    ☒Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    **On March 29, 2021 and July 19, 2021, Olink Holding AB registered American Depositary Shares (“ADSs”) (each representing one Common Share).

     

    ***CUSIP assigned to the ADSs, which are listed on The Nasdaq Global Market.

     

     

     

     

    CUSIP No. 680710100

    Page 2 of 10

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Summa Equity AB

     

    Not applicable

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Sweden

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    0. See Item 4.

    6

    SHARED VOTING POWER

     

    77,366,054. See Item 4.

    7

    SOLE DISPOSITIVE POWER

     

    0. See Item 4.

    8

    SHARED DISPOSITIVE POWER

     

    77,366,054. See Item 4.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    77,366,054. See Item 4.

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    65,01%. See Item 4.

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

     

    CUSIP No. 680710100

    Page 3 of 10

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Knilo InvestCo AB

     

    Not applicable

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Sweden

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    12,170,769. See Item 4.

    6

    SHARED VOTING POWER

     

    0. See Item 4.

    7

    SOLE DISPOSITIVE POWER

     

    12,170,769 . See Item 4.

    8

    SHARED DISPOSITIVE POWER

     

    0. See Item 4.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    12,170,769. See Item 4.

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)     ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    10.23%. See Item 4.

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

     

    CUSIP No. 680710100

    Page 4 of 10

     

    1

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Knilo InvestCo II AB

     

    Not applicable

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Sweden

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    65,106,836. See Item 4.

    6

    SHARED VOTING POWER

     

    0. See Item 4.

    7

    SOLE DISPOSITIVE POWER

     

    65,106,836. See Item 4.

    8

    SHARED DISPOSITIVE POWER

     

    0. See Item 4.

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    65,106,836. See Item 4.

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)     ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    54,71%. See Item 4.

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

     

    CUSIP No. 680710100

    Page 5 of 10

     

    Item 1.

     

    (a)Name of Issuer:

     

    Olink Holding AB (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    Uppsala Science Park

    SE-751 83

    Uppsala, Sweden

     

    Item 2.

     

    (a)Name of Person Filing:

     

    Summa Equity AB

    Knilo InvestCo AB

    Knilo InvestCo II AB

    (each a “Reporting Person” and collectively, the “Reporting Persons”). This Schedule 13G is being filed pursuant to a Joint Filing Agreement (the “Joint Filing Agreement”), attached hereto as Exhibit 1.

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    Birger Jarlsgatan 27SE-111 45

    Stockholm, Sweden

     

    (c)Citizenship:

     

    See the responses to Item 4 of the attached cover pages.

     

    (d)Title of Class of Securities:

     

    Common Shares, no par value (“Common Shares”)

    American Depositary Shares (“ADSs”), each representing one Common Share

     

     

    (e)CUSIP Number:

     

    680710100 (ADSs)

     

     

    CUSIP No. 680710100

    Page 6 of 10

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.

     

    Provide the following information regarding the aggregate number and percent of the class of securities of the Issuer identified in Item 1.

     

    (a)Amount beneficially owned: See Item 4(b) below.

     

    (b)Number and percent of shares beneficially owned as of December 31, 2021 by each Reporting Person:

     

    Reporting Person

      Number of Common Shares   Percentage of Class 
    Summa Equity AB   77,366,054    64,94%(1)
    Knilo InvestCo AB   12,170,769    10,23%(1)
    Knilo InvestCo II AB   65,106,836    54,71%(1)

     

     

    CUSIP No. 680710100

    Page 7 of 10

     

    (c) Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote. Number of Common Shares beneficially owned as of December 31, 2021, as to which each Reporting Person has sole power to vote or direct the vote:

     

    Reporting Person

      Number of Common Shares 
    Summa Equity AB   0 
    Knilo InvestCo AB   0 
    Knilo InvestCo II AB   0 

     

    (ii)Shared power to vote or to direct the vote. Number of Common Shares beneficially owned as of December 31, 2021, as to which each Reporting Person has shared power to vote or direct the vote:

     

    Reporting Person

      Number of Common Shares 
    Summa Equity AB(2)   77,366,054 
    Knilo InvestCo AB   0 
    Knilo InvestCo II AB   0 

     

    (iii)Sole power to dispose or to direct the disposition of. Number of Common Shares beneficially owned as of December 31, 2021, as to which each Reporting Person has sole power to dispose or to direct the disposition of:

     

    Reporting Person

      Number of Common Shares 
    Summa Equity AB   0 
    Knilo InvestCo AB   0 
    Knilo InvestCo II AB   0 

     

    (iv)Shared power to dispose or to direct the disposition of. Number of Common Shares beneficially owned as of December 31, 2021, as to which each Reporting Person has shared power to dispose or to direct the disposition of:

     

    Reporting Person

      Number of Common Shares 
    Summa Equity AB(2)   77,366,054 
    Knilo InvestCo AB   0 
    Knilo InvestCo II AB   0 

     

    (1)Based on 119,007,062 Common Shares outstanding as of December 31, 2021, as provided by the Issuer to the Reporting Person.
    (2)As the holder of the majority of the votes of Knilo ManCo AB, Knilo InvestCo AB may be deemed to have voting and dispositive power over the 88,449 shares held by Knilo ManCo AB. For the avoidance of doubt, Knilo InvestCo AB expressly disclaims beneficial ownership of such shares except to the extent of any pecuniary interest it may have therein. Knilo InvestCo II AB is wholly owned by Knilo InvestCo AB. Summa Equity AB, indirectly through intermediary funds and coinvestment entities, is the sole shareholder of Knilo InvestCo AB. Summa Equity AB has also been designated as the sole manager of such intermediary funds and co-investment entities. Summa Equity AB is authorized by the Swedish Financial Supervision Authority (the SFSA) to conduct business under the Alternative Investment Fund Managers Directive (2011/61/EU) (as enacted in Sweden) and is thereby under the supervision of the SFSA. The voting and dispositive decisions of Summa Equity AB are made by its board of directors, the members of which are Reynir Indahl, Eva Broms, Camilla Melander Gustafsson and Mirja Lehmler-Brown. Each member of Summa Equity AB’s board of directors disclaims any beneficial ownership of the reported shares.

     

     

    CUSIP No. 680710100

    Page 8 of 10

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of a Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    Not applicable.

     

     

    CUSIP No. 680710100

    Page 9 of 10

     

    Exhibit

     

    Description of Exhibit

    1   Joint Filing Agreement, dated as of February 14, 2022, among the Reporting Persons.

     

     

    CUSIP No. 680710100

    Page 10 of 10

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

    Summa Equity AB

     

      By: /s/ Karin Cakste
      Name:  Karin Cakste
      Title: Chief Executive Officer
         
     

    Knilo InvestCo AB

       
      By: /s/ Tommi Unkuri
      Name: Tommi Unkuri
      Title: Board Member
         
     

    Knilo InvestCo II AB 

       
      By: /s/ Tommi Unkuri
      Name: Tommi Unkuri
      Title: Deputy Board Member

     

    [Signature page to Schedule 13G 2022]

     

     

     

     

     

    Get the next $OLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLK

    DatePrice TargetRatingAnalyst
    1/5/2023$27.00Sector Outperform
    Scotiabank
    12/14/2022$28.00Buy
    Canaccord Genuity
    2/14/2022$33.00 → $32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $OLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notice to attend the Extra General Meeting of Olink Holding AB (publ)

      This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, July 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CEST on Tuesday 6 August 2024, in the Company's facilities at Salagatan 16F, Uppsala. Registration for the meeting commences at 3:30 p.m. CEST. NOTICE OF PARTICIPATION Shareholders who wish to attend in the proceedings of the Extra General Meeting must: be entered in the share register kept on behalf of the Company by Eur

      7/11/24 4:05:45 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period

      Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) ("Olink") (NASDAQ:OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. "We are excited to welcome Olink colleagues to Thermo Fisher," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Protein research

      7/10/24 8:00:00 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components
    • Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

      UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced that the UK Competition and Markets Authority (the "CMA") has unconditionally approved the previously announced tender offer (the "Offer") by Orion Acquisition AB (the "Buyer"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher" or "Parent"), for all outstanding Common Shares and American Depositary Shares (together, the "Shares") of Olink for $26.00 per Share. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fis

      7/8/24 7:37:45 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components

    $OLK
    Financials

    Live finance-specific insights

    See more
    • Olink reports first quarter 2024 financial results

      UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024. Highlights First quarter 2024 revenue totaled $28.8 million, representing year over year growth of 5% on a reported basis and 5% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 121, with 14 installations during the first quarterTotal Signature Q100 placements reached 202, with 16 placements during the first quarterExplore revenue of $18.0 million accounted for 63% of total first quarter revenue, with Explore Kit revenue totaling $11.3 million, or 63% of t

      5/13/24 6:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024

      UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the "AGM") of Olink Holding AB (publ), reg. no 559189-7755, (the "Company"), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com. Adoption of the balance sheet and income statement, disposition regarding the Company's results and discharge from liabilityThe AGM adopted the Company's income statement and balance sheet and the consolidated income statement an

      4/19/24 4:05:00 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Olink reports fourth quarter and full year 2023 financial results

      UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis and 17% on a constant currency adjusted like-for-like basisFull year revenue 2023 revenue totaled $169.6 million, achieving year over year growth of 21% on a reported basis and 21% on a constant currency adjusted like-for-like basisTotal Explore customer installations reached 107, with 20 installations during the fourth quarterTotal Signature Q100 placements reached 186, wit

      3/25/24 8:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Olink Holding AB

      15F-12B - Olink Holding AB (publ) (0001835539) (Filer)

      7/22/24 5:19:56 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 6-K filed by Olink Holding AB

      6-K - Olink Holding AB (publ) (0001835539) (Filer)

      7/22/24 8:30:04 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 14D9/A filed by Olink Holding AB

      SC 14D9/A - Olink Holding AB (publ) (0001835539) (Subject)

      7/17/24 8:30:07 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Olink Holding with a new price target

      Scotiabank initiated coverage of Olink Holding with a rating of Sector Outperform and set a new price target of $27.00

      1/5/23 7:46:07 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Canaccord Genuity initiated coverage on Olink Holding with a new price target

      Canaccord Genuity initiated coverage of Olink Holding with a rating of Buy and set a new price target of $28.00

      12/14/22 8:56:12 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Olink Holding with a new price target

      Morgan Stanley reiterated coverage of Olink Holding with a rating of Equal-Weight and set a new price target of $32.00 from $33.00 previously

      2/14/22 8:24:48 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Olink Holding AB (Amendment)

      SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)

      2/14/24 10:03:04 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Olink Holding AB

      SC 13G - Olink Holding AB (publ) (0001835539) (Subject)

      2/9/24 7:59:50 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Olink Holding AB (Amendment)

      SC 13G/A - Olink Holding AB (publ) (0001835539) (Subject)

      11/13/23 9:02:39 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OLK
    Leadership Updates

    Live Leadership Updates

    See more
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar

      6/6/23 8:00:00 AM ET
      $DNLI
      $DVA
      $EVLO
      $FHTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Misc Health and Biotechnology Services
      Biotechnology: Pharmaceutical Preparations
    • Bruno Rossi joins Olink as Chief Commercial Officer

      UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately. Mr. Rossi will lead the Company's global commercial organization including Sales, Marketing and Sales Operations. He will report to Carl Raimond, President of Olink. "I am delighted to welcome Bruno to the Olink organization, and look forward to the value his considerable industry experience will add to our rapidly growing company." said Carl Raimond, President of Olink. "Over the past two years, Olink has experienced remarkable growth. We have a

      3/21/23 8:00:00 AM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials